Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors

Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors

Prevalence of potential drug-drug interactions (PDDIs) between antiretroviral drugs (ARVs) and co-medications was high in 2008 in a Swiss HIV Cohort Study (SHCS) survey. We reassessed the prevalence of PDDIs in the era of human immunodeficiency virus (HIV) integrase inhibitors (INIs), characterized...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases Vol. 73; no. 7; pp. e2145 - e2152
Main Authors: Deutschmann, Elisabeth, Bucher, Heiner C, Jaeckel, Steffen, Gibbons, Sara, McAllister, Katie, Scherrer, Alexandra U, Braun, Dominique L, Cavassini, Matthias, Hachfeld, Anna, Calmy, Alexandra, Battegay, Manuel, Cipriani, Michela, Elzi, Luigia, Young, James, Lopez-Centeno, Beatriz, Berenguer, Juan, Khoo, Saye, Moffa, Giusi, Marzolini, Catia
Format: Journal Article
Language:English
Published: United States 05-10-2021
Subjects:
Aged
Cohort Studies
Drug Interactions
HIV Infections - drug therapy
HIV Infections - epidemiology
HIV Integrase Inhibitors - adverse effects
Humans
Male
Middle Aged
Pharmaceutical Preparations
Prevalence
Switzerland - epidemiology
Switzerland
Swiss HIV Cohort Study
modern antiretroviral therapy
prevalence
HIV
drug–drug interactions
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prevalence of potential drug-drug interactions (PDDIs) between antiretroviral drugs (ARVs) and co-medications was high in 2008 in a Swiss HIV Cohort Study (SHCS) survey. We reassessed the prevalence of PDDIs in the era of human immunodeficiency virus (HIV) integrase inhibitors (INIs), characterized by more favorable interaction profiles. The prevalence of PDDIs in treated HIV-positive individuals was assessed for the period 01-12/2018 by linkage of the Liverpool HIV drug interactions and SHCS databases. PDDIs were categorized as harmful (red flagged), of potential clinical relevance (amber flagged), or of weak clinical significance (yellow flagged). In 9298 included individuals, median age was 51 years (IQR, 43-58), and 72% were males. Individuals received unboosted INIs (40%), boosted ARVs (30%), and nonnucleoside reverse transcriptase inhibitor (NNRTIs) (32%)-based regimens. In the entire cohort, 68% received ≥1 co-medication, 14% had polypharmacy (≥5 co-medications) and 29% had ≥1 PDDI. Among individuals with co-medication, the prevalence of combined amber and yellow PDDIs was 43% (33% amber-mostly with cardiovascular drugs-and 20% yellow-flagged PDDIs) compared to 59% in 2008. Two percent had red-flagged PDDIs (mostly with corticosteroids), the same as in the 2008 survey. Compared with 2008, fewer individuals received boosted ARVs (-24%) and NNRTIs (-13%) but the use of co-medications was higher. Prevalence of PDDIs was lower with more widespread use of INIs in 2018 than in 2008. Continued use of boosted regimens and increasing needs for co-medications in this aging population impeded lower rates of PDDIs.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciaa918